Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

Abstract FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (GAs) in tumor tissues or circulating...

Full description

Bibliographic Details
Main Authors: Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Masaru Katoh, Simona Tavolari
Format: Article
Language:English
Published: Nature Portfolio 2024-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-52991-8

Internet

https://doi.org/10.1038/s41598-024-52991-8

Similar Items